Frequent involvement of chromatin remodeler alterations in gastric field cancerization

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 328-338

  Takeshima, Hideyuki ^a   Niwa, Tohru ^a   Takahashi, Takamasa ^a   Wakabayashi, Mika ^a   Yamashita, Satoshi ^a   Ando, Takayuki ^b   Inagawa, Yuki ^a   Taniguchi, Hirokazu ^c   Katai, Hitoshi ^c   Sugiyama, Toshiro ^b   Kiyono, Tohru ^a   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chromatin remodeling; DNA methylation; Epigenetics; Field defect

Indexed keywords

ACTL6B GENE; ARID1A GENE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CHROMATIN; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE ISOLATION; GENE SILENCING; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; SMARCA1 GENE; SMARCA2 GENE; SMARCA4 GENE; SOMATIC MUTATION; STOMACH CANCER; TISSUE SECTION; CARCINOGENESIS; CASE CONTROL STUDY; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; RISK FACTOR; STOMACH MUCOSA; STOMACH TUMOR; TUMOR CELL LINE;

CHROMATIN; DNA BINDING PROTEIN; SMARCA1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

CARCINOGENESIS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHROMATIN; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GASTRIC MUCOSA; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; RISK FACTORS; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84920389848     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.038     Document Type: Article

References (53)

1. Braakhuis B.J., Tabor M.P., Kummer J.A., Leemans C.R., Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003, 63:1727-1730.
2. Slaughter D.P., Southwick H.W., Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6:963-968.
3. Nakajima T., Oda I., Gotoda T., Hamanaka H., Eguchi T., Yokoi C., et al. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance?. Gastric Cancer 2006, 9:93-98.
4. Ushijima T. Epigenetic field for cancerization. J. Biochem. Mol. Biol 2007, 40:142-150.
5. Maekita T., Nakazawa K., Mihara M., Nakajima T., Yanaoka K., Iguchi M., et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res 2006, 12:989-995.
6. Nakajima T., Maekita T., Oda I., Gotoda T., Yamamoto S., Umemura S., et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol. Biomarkers Prev 2006, 15:2317-2321.
7. Issa J.P., Ahuja N., Toyota M., Bronner M.P., Brentnall T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001, 61:3573-3577.
8. Eads C.A., Lord R.V., Kurumboor S.K., Wickramasinghe K., Skinner M.L., Long T.I., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000, 60:5021-5026.
9. Kondo Y., Kanai Y., Sakamoto M., Mizokami M., Ueda R., Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000, 32:970-979.
10. Arai E., Kanai Y., Ushijima S., Fujimoto H., Mukai K., Hirohashi S. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int. J. Cancer 2006, 119:288-296.
11. Ando T., Yoshida T., Enomoto S., Asada K., Tatematsu M., Ichinose M., et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int. J. Cancer 2009, 124:2367-2374.
12. Niwa T., Tsukamoto T., Toyoda T., Mori A., Tanaka H., Maekita T., et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010, 70:1430-1440.
13. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med 2001, 345:784-789.
14. K. Asada, T. Nakajima, T. Shimazu, N. Yamamichi, T. Maekita, C. Yokoi, etal., Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study, Gut (Online). http://gut.bmj.com/content/early/2014/06/02/gutjnl-2014-307094.long.
15. Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513:202-209. http://www.nature.com/nature/journal/v513/n7517/full/nature13480.html.
16. Helming K.C., Wang X., Roberts C.W. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 2014, 26:309-317.
17. Kakiuchi M., Nishizawa T., Ueda H., Gotoh K., Tanaka A., Hayashi A., et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat. Genet 2014, 46:583-587.
18. Wang K., Yuen S.T., Xu J., Lee S.P., Yan H.H., Shi S.T., et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet 2014, 46:573-582.
19. Yamamoto E., Suzuki H., Takamaru H., Yamamoto H., Toyota M., Shinomura Y. Role of DNA methylation in the development of diffuse-type gastric cancer. Digestion 2011, 83:241-249.
20. Y. Yoda, H. Takeshima, T. Niwa, J.G. Kim, T. Ando, R. Kushima, etal., Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer, Gastric Cancer (Online). http://link.springer.com/article/10.1007%2Fs10120-014-0348-0.
21. Wang K., Kan J., Yuen S.T., Shi S.T., Chu K.M., Law S., et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet 2011, 43:1219-1223.
22. Wang X., Haswell J.R., Roberts C.W. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer - mechanisms and potential therapeutic insights. Clin. Cancer Res 2014, 20:21-27.
23. Zang Z.J., Cutcutache I., Poon S.L., Zhang S.L., McPherson J.R., Tao J., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet 2012, 44:570-574.
24. Wilson B.G., Roberts C.W. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 2011, 11:481-492.
25. Okamoto T., Aoyama T., Nakayama T., Nakamata T., Hosaka T., Nishijo K., et al. Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells. Biochem. Biophys. Res. Commun 2002, 295:354-361.
26. Sasaki R., Narisawa-Saito M., Yugawa T., Fujita M., Tashiro H., Katabuchi H., et al. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis 2009, 30:423-431.
27. Kim J.G., Takeshima H., Niwa T., Rehnberg E., Shigematsu Y., Yoda Y., et al. Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers. Cancer Lett 2013, 330:33-40.
28. Asada K., Ando T., Niwa T., Nanjo S., Watanabe N., Okochi-Takada E., et al. FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect. Oncogene 2013, 32:2140-2149.
29. Takeshima H., Yamashita S., Shimazu T., Niwa T., Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res 2009, 19:1974-1982.
30. Takahashi T., Matsuda Y., Yamashita S., Hattori N., Kushima R., Lee Y.C., et al. Estimation of the fraction of cancer cells in a tumor DNA sample using DNA methylation. PLoS ONE 2013, 8:e82302.
31. Naito Y., Yoshimura J., Morishita S., Ui-Tei K. siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics 2009, 10:392.
32. Kikuyama M., Takeshima H., Kinoshita T., Okochi-Takada E., Wakabayashi M., Akashi-Tanaka S., et al. Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation. Cancer Lett 2012, 322:204-212.
33. Okochi-Takada E., Nakazawa K., Wakabayashi M., Mori A., Ichimura S., Yasugi T., et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int. J. Cancer 2006, 119:1338-1344.
34. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4:P3.
35. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc 2009, 4:44-57.
36. Ushijima T., Hattori N. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin. Cancer Res 2012, 18:923-929.
37. Enomoto S., Maekita T., Tsukamoto T., Nakajima T., Nakazawa K., Tatematsu M., et al. Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non-cancerous gastric mucosae. Cancer Sci 2007, 98:1853-1861.
38. Weaver J.M., Ross-Innes C.S., Shannon N., Lynch A.G., Forshew T., Barbera M., et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet 2014, (in press).
39. Mullighan C.G. TET2 mutations in myelodysplasia and myeloid malignancies. Nat. Genet 2009, 41:766-767.
40. Rivera M.N., Kim W.J., Wells J., Driscoll D.R., Brannigan B.W., Han M., et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007, 315:642-645.
41. Van Vlierberghe P., Palomero T., Khiabanian H., Van der Meulen J., Castillo M., Van Roy N., et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat. Genet 2010, 42:338-342.
42. Wang L., Liu R., Li W., Chen C., Katoh H., Chen G.Y., et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009, 16:336-346.
43. Zuo T., Wang L., Morrison C., Chang X., Zhang H., Li W., et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129:1275-1286.
44. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899.
45. De Smet C., Loriot A., Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol. Cell. Biol 2004, 24:4781-4790.
46. Hahn M.A., Hahn T., Lee D.H., Esworthy R.S., Kim B.W., Riggs A.D., et al. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 2008, 68:10280-10289.
47. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet 2007, 39:237-242.
48. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet 2007, 39:232-236.
49. Song J.Z., Stirzaker C., Harrison J., Melki J.R., Clark S.J. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002, 21:1048-1061.
50. Takeshima H., Ushijima T. Methylation destiny: Moira takes account of histones and RNA polymerase II. Epigenetics 2010, 5:89-95.
51. Takeshima H., Yamashita S., Shimazu T., Ushijima T. Effects of genome architecture and epigenetic factors on susceptibility of promoter CpG islands to aberrant DNA methylation induction. Genomics 2011, 98:182-188.
52. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., et al. Epigenetic stem cell signature in cancer. Nat. Genet 2007, 39:157-158.
53. Euskirchen G.M., Auerbach R.K., Davidov E., Gianoulis T.A., Zhong G., Rozowsky J., et al. Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches. PLoS Genet 2011, 7:e1002008.